Crimson Publishers Publish With Us Reprints e-Books Video articles


Research in Pediatrics & Neonatology

Does COVID-19 Uses ACE-2-Receptors of the Epidermis As Entry into the Body?

Submission: April 11, 2020; Published: April 20, 2020

ISSN : 2576-9200
Volume4 Issue3


Since the outbreak in China in December 2019 researchers searching for adequate therapy to control viral spreading and to inhibit COVID-19 effectively. To date, no effective drug to treat this severe viral infection was found. Publications about angiotensin II receptor blocker reveal a new effective method to think about in treating COVID-19 [1-5]. Moreover, different therapy options were started to stop the devastating potential of COVID-19 worldwide. Antibody-rich donated plasma from survivors, different inhibitors are part of analysis to stop the entry of the virus into the cell and disturb the connection between SARS-CoV-2 and angiotensin-2 receptor binding. Angiotensin II and the receptor play an important role in cell entry of COVID-19. For cell entry COVID-19 needs the presence of a serine protease TMPRSS2 and cathepsin L [6-9].

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137